IN2014CN00373A - - Google Patents

Download PDF

Info

Publication number
IN2014CN00373A
IN2014CN00373A IN373CHN2014A IN2014CN00373A IN 2014CN00373 A IN2014CN00373 A IN 2014CN00373A IN 373CHN2014 A IN373CHN2014 A IN 373CHN2014A IN 2014CN00373 A IN2014CN00373 A IN 2014CN00373A
Authority
IN
India
Prior art keywords
signal
isv
give rise
tendency
protein interference
Prior art date
Application number
Other languages
English (en)
Inventor
Judith Baumeister
Marie Paule Lucienne Armanda Bouche
Carlo Boutton
Marie Ange Buyse
Veerle Snoeck
Stephanie Staelens
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47423024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014CN00373(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2011/067132 external-priority patent/WO2012042026A1/en
Priority claimed from PCT/EP2012/061304 external-priority patent/WO2012175400A1/en
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of IN2014CN00373A publication Critical patent/IN2014CN00373A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
IN373CHN2014 2011-06-23 2012-06-25 IN2014CN00373A (enExample)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161500464P 2011-06-23 2011-06-23
US201161500360P 2011-06-23 2011-06-23
US201161541368P 2011-09-30 2011-09-30
PCT/EP2011/067132 WO2012042026A1 (en) 2010-09-30 2011-09-30 Biological materials related to c-met
US13/435,567 US8703135B2 (en) 2010-09-30 2012-03-30 Biological materials related to c-Met
PCT/EP2012/061304 WO2012175400A1 (en) 2011-06-23 2012-06-14 Serum albumin binding proteins
PCT/EP2012/062251 WO2012175741A2 (en) 2011-06-23 2012-06-25 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

Publications (1)

Publication Number Publication Date
IN2014CN00373A true IN2014CN00373A (enExample) 2015-04-03

Family

ID=47423024

Family Applications (1)

Application Number Title Priority Date Filing Date
IN373CHN2014 IN2014CN00373A (enExample) 2011-06-23 2012-06-25

Country Status (23)

Country Link
US (11) US20180009888A9 (enExample)
EP (1) EP2723769B2 (enExample)
JP (6) JP6258199B2 (enExample)
KR (7) KR102880093B1 (enExample)
CN (5) CN108659120A (enExample)
AU (7) AU2012273929B2 (enExample)
BR (3) BR122017005075B1 (enExample)
CA (3) CA3142288A1 (enExample)
DK (1) DK2723769T4 (enExample)
ES (1) ES2622006T5 (enExample)
HU (1) HUE031828T2 (enExample)
IL (4) IL293163A (enExample)
IN (1) IN2014CN00373A (enExample)
LT (1) LT2723769T (enExample)
MX (2) MX350074B (enExample)
NZ (1) NZ780183A (enExample)
PH (7) PH12022550311A1 (enExample)
PL (1) PL2723769T5 (enExample)
PT (1) PT2723769T (enExample)
RU (1) RU2700630C2 (enExample)
SG (4) SG194982A1 (enExample)
WO (1) WO2012175741A2 (enExample)
ZA (1) ZA201309295B (enExample)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2860453T3 (es) 2009-10-30 2021-10-05 Novartis Ag Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III
ES2659406T3 (es) 2010-05-06 2018-03-15 Novartis Ag Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
EP3363813A1 (en) 2011-06-23 2018-08-22 Ablynx NV Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
NZ780183A (en) * 2011-06-23 2024-12-20 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2723771B1 (en) 2011-06-23 2019-09-11 Ablynx NV Serum albumin binding proteins
PE20141522A1 (es) * 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
WO2013073968A2 (en) * 2011-09-12 2013-05-23 Industrial Research Limited Agents for modulation of cell signalling
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
MX2014005411A (es) 2011-11-04 2015-02-12 Novartis Ag Construcciones prolongadas de la vida media de la proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
EP2895510A2 (en) * 2012-09-13 2015-07-22 Novartis AG Single domain antibody with c-terminal modification
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
EP3143403B1 (en) * 2014-05-16 2021-10-27 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
PT3248986T (pt) 2014-05-16 2022-04-05 Ablynx Nv Domínios variáveis de imunoglobulina
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
WO2016118733A1 (en) 2015-01-21 2016-07-28 Inhibrx Biopharma LLC Non-immunogenic single domain antibodies
CA2981098A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker
HK1250040A1 (zh) 2015-03-31 2018-11-23 Sorriso Pharmaceuticals, Inc. 多肽
JP6895421B2 (ja) 2015-03-31 2021-06-30 ブイエイチスクエアード リミテッド ポリペプチド
ES3029413T3 (en) 2015-04-02 2025-06-24 Ablynx Nv Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
SI3294319T1 (sl) 2015-05-13 2024-09-30 Ablynx Nv Polipeptidi, ki rekrutirajo celice T na osnovi reaktivnosti CD3
EP3611192B1 (en) 2015-05-13 2025-03-05 Ablynx N.V. T cell recruiting polypeptides based on tcr alpha/beta reactivity
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
RU2018119732A (ru) 2015-10-30 2019-12-03 Аблинкс Нв Полипептиды против il-23
TWI746473B (zh) * 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
AU2016352695B2 (en) * 2015-11-12 2023-07-27 Ablynx Nv Improved P2X7 receptor binders and polypeptides comprising the same
NO2768984T3 (enExample) * 2015-11-12 2018-06-09
EP3974449A1 (en) * 2015-11-13 2022-03-30 Ablynx NV Improved serum albumin-binding immunoglobulin variable domains
SG10201911035QA (en) 2015-11-18 2020-01-30 Merck Sharp & Dohme Pd1 and/or lag3 binders
CN120535622A (zh) * 2015-11-18 2025-08-26 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
HK1254952A1 (zh) 2015-11-18 2019-08-02 Merck Sharp & Dohme Llc Ctla4结合剂
CN109071639B (zh) 2015-11-18 2022-07-08 默沙东公司 Pd1/ctla4结合剂
CA3006398A1 (en) 2015-11-27 2017-06-01 Ablynx Nv Polypeptides inhibiting cd40l
MA54648A (fr) 2015-12-04 2021-11-10 Boehringer Ingelheim Int Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
CA3029133C (en) * 2016-06-23 2024-04-30 Ablynx N.V. Improved pharmacokinetic assays for immunoglobulin single variable domains
EP3512880A1 (en) 2016-09-15 2019-07-24 Ablynx NV Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
CN110494543A (zh) 2016-10-19 2019-11-22 弗洛设计声能学公司 通过声学的亲和细胞提取
AU2017361846B2 (en) 2016-11-16 2024-08-22 Ablynx Nv T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
CN117164710A (zh) 2016-12-07 2023-12-05 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白单可变结构域
ES2991459T3 (es) 2017-01-17 2024-12-03 Ablynx Nv Ligantes de albúmina sérica mejorados
SG10202108973SA (en) 2017-01-17 2021-09-29 Ablynx Nv Improved serum albumin binders
AU2018241286B2 (en) 2017-03-31 2025-03-13 Ablynx N.V. Improved immunogenicity assays
US11033636B2 (en) 2017-05-31 2021-06-15 Boehringer Ingelheim International Gmbh Polypeptides antagonizing Wnt signaling in tumor cells
IL270951B2 (en) 2017-06-02 2025-05-01 Merck Patent Gmbh ADAMTS5, MMP13 and aggrecan-binding polypeptides
LT3630847T (lt) 2017-06-02 2024-12-10 Merck Patent Gmbh Adamts surišantys imunoglobulinai
CN110997716B (zh) 2017-06-02 2024-03-15 埃博灵克斯股份有限公司 结合聚集蛋白聚糖的免疫球蛋白
KR102778120B1 (ko) 2017-06-02 2025-03-06 메르크 파텐트 게엠베하 Mmp13 결합성 면역글로불린
CA3070253A1 (en) 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
EP3674191B1 (en) 2017-08-23 2021-07-14 Honda Motor Co., Ltd. Air bag device for saddle-type vehicles
WO2019086548A1 (en) 2017-10-31 2019-05-09 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
KR20220066413A (ko) 2017-12-14 2022-05-24 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
MA53130A (fr) 2018-07-10 2021-05-19 Regeneron Pharma Procédés d'atténuation d'interférence de cible médicamenteuse dans un dosage immunologique d'anticorps anti-médicament (ada)
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
EP3962599A1 (en) 2019-04-30 2022-03-09 Vib Vzw Cystic fibrosis transmembrane conductance regulator stabilizing agents
EP3986931A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
AU2020294980A1 (en) 2019-06-21 2022-02-17 Sorriso Pharmaceuticals, Inc. Polypeptides
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
GB201914468D0 (en) 2019-10-07 2019-11-20 Crescendo Biologics Ltd Binding Molecules
WO2021105438A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
CA3163764A1 (en) 2019-12-06 2021-06-10 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
CN114981300B (zh) 2019-12-06 2025-10-31 艾伯霖克斯公司 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
AU2020400938A1 (en) 2019-12-09 2022-07-28 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP
EP4077372A1 (en) 2019-12-20 2022-10-26 Vib Vzw Nanobody exchange chromatography
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
JP2023514654A (ja) 2020-02-25 2023-04-06 ブイアイビー ブイゼットダブリュ ロイシンリッチリピートキナーゼ２のアロステリック調節因子
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
CA3195687A1 (en) 2020-09-25 2022-03-31 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
JP2023552865A (ja) 2020-12-14 2023-12-19 武田薬品工業株式会社 条件付き二重特異性結合タンパク質
IL303783A (en) 2020-12-18 2023-08-01 Sanofi Sa Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
KR20230123497A (ko) 2020-12-18 2023-08-23 아블린쓰 엔.브이. IL-6 및 TNF-α를 표적화하는 면역글로불린 단일 가변도메인을 포함하는 폴리펩티드
WO2022129637A1 (en) 2020-12-18 2022-06-23 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
KR20230141853A (ko) 2021-02-05 2023-10-10 브이아이비 브이지더블유 사베코바이러스 결합제
EP4294516A1 (en) 2021-02-19 2023-12-27 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
CN113173978B (zh) * 2021-04-22 2024-03-01 温州医科大学 一种对hpv16e6蛋白具有结合亲和力的多肽及其应用
EP4377352A2 (en) 2021-07-30 2024-06-05 Vib Vzw Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
US20250026842A1 (en) * 2021-11-29 2025-01-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Modified protein or polypeptide
US20250051826A1 (en) 2021-12-13 2025-02-13 Heraeus Medical Gmbh Tests and methods for detecting bacterial infection
EP4448574A1 (en) 2021-12-17 2024-10-23 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting tcralphabeta, cd33 and cd123
EP4463479A1 (en) 2022-01-12 2024-11-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
TW202342521A (zh) 2022-02-23 2023-11-01 日商武田藥品工業股份有限公司 條件性雙特異性結合蛋白
EP4508082A1 (en) 2022-04-13 2025-02-19 Vib Vzw An ltbr agonist in combination therapy against cancer
US20250313611A1 (en) 2022-05-18 2025-10-09 Vib Vzw Sarbecovirus spike s2 subunit binders
WO2023240156A1 (en) 2022-06-08 2023-12-14 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
US20240109965A1 (en) 2022-06-14 2024-04-04 Ablynx N.V. Immunoglobulin single variable domains targeting t cell receptor
JP2025526384A (ja) 2022-07-27 2025-08-13 アブリンクス エン．ヴェー． 新生児型Ｆｃ受容体の特異的エピトープに結合するポリペプチド
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
EP4357778A1 (en) 2022-10-20 2024-04-24 Heraeus Medical GmbH Treatment of microbial infections diagnosed using the biomarker d-lactate
EP4638502A2 (en) 2022-12-21 2025-10-29 Genzyme Corporation Anti-pd-1×4-1bb binding proteins
TW202440614A (zh) 2022-12-23 2024-10-16 比利時商艾伯霖克斯公司 基於蛋白質的接合載體
AU2024207151A1 (en) 2023-01-09 2025-06-19 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
CN121013866A (zh) 2023-02-10 2025-11-25 阿穆尼克斯制药公司 靶向前列腺特异性膜抗原（psma）的组合物及其制备和使用方法
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
TW202444757A (zh) 2023-03-14 2024-11-16 美商奧迪希治療公司 抗cd25抗原結合蛋白及其用途
AU2024243709A1 (en) 2023-04-03 2025-11-06 Katholieke Universiteit Leuven Blood-brain barrier crossing antibodies
CN121079319A (zh) 2023-05-08 2025-12-05 赛诺菲 免疫球蛋白单可变结构域的糖基化
TW202448951A (zh) 2023-05-17 2024-12-16 美商奧迪希治療公司 經修飾之單域抗體
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
TW202515917A (zh) 2023-06-29 2025-04-16 美商奧迪希治療公司 抗trailr2抗原結合蛋白及其用途
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
WO2025051767A1 (en) 2023-09-04 2025-03-13 Sanofi Polypeptides for use in the treatment of glypican-3-expressing tumours
AR133903A1 (es) 2023-09-22 2025-11-12 Ablynx Nv Agentes de unión de albúmina bi- y multivalentes
TW202530265A (zh) 2023-10-13 2025-08-01 美商奧迪希治療公司 抗cdh17抗原結合蛋白及其用途
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
WO2025114529A1 (en) 2023-12-01 2025-06-05 Ablynx Nv Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
US20250236673A1 (en) 2023-12-22 2025-07-24 Ablynx N.V. Protein-based carriers for site-specific amine conjugation
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
WO2025174825A2 (en) 2024-02-12 2025-08-21 Aera Therapeutics, Inc. Delivery compositions
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545106C3 (de) 1963-07-16 1979-05-31 Union Carbide Corp., New York, N.Y. (V.St.A.) Verfahren zur Herstellung von linearen Polyarylenpolyäthern
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9016299D0 (en) * 1990-07-25 1990-09-12 Brien Caroline J O Binding substances
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
ES2103770T3 (es) 1990-11-26 1997-10-01 Akzo Nobel Nv Procedimiento de produccion de anticuerpos monoclonales.
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
ES2358576T3 (es) 1999-07-05 2011-05-11 K.U. LEUVEN RESEARCH & DEVELOPMENT Detección de la actividad del factor de von-willebrand (vwf).
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
AU2001289930A1 (en) 2000-09-25 2002-04-08 Rega Stichting Vzw Method for the production of human antibodies, antibodies thus obtained and their use in therapy and diagnosis
EP1360207B1 (en) 2000-12-13 2011-06-22 Bac Ip B.V. Protein arrays of camelid heavy-chain immunoglobulin variable domains
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1570267B1 (en) 2002-12-03 2011-10-12 UCB Pharma, S.A. Assay for identifying antibody producing cells
CA2511910A1 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
NZ540771A (en) 2003-01-10 2009-05-31 Ablynx Nv Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
US20050079574A1 (en) * 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
US20070087331A1 (en) 2003-05-15 2007-04-19 Cytos Biotechnology Ag Selection of b cells with specificity if interest: method of preparation and use
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
KR20060083227A (ko) 2003-11-04 2006-07-20 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 고지혈증·고알부민혈증 모델 동물
US7476724B2 (en) 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
KR20070086896A (ko) 2004-12-02 2007-08-27 도만티스 리미티드 항­ｉｌ­1ｒ1 단일 도메인 항체 및 치료적 용도
CA2595682A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
CN101213214B (zh) * 2005-05-20 2014-06-25 埃博灵克斯股份有限公司 针对冯威勒布兰特因子的单一结构域vhh抗体
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
JP2007008925A (ja) * 2005-05-31 2007-01-18 Canon Inc 標的物質捕捉分子
WO2006129843A2 (en) 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Bispecific capturing molecule
US7875465B2 (en) 2005-05-31 2011-01-25 Canon Kabushiki Kaisha Target substance capturing molecule
KR20080077238A (ko) 2005-12-01 2008-08-21 도만티스 리미티드 인터루킨 1 수용체 타입 1에 결합하는 비경쟁적 도메인항체 포맷
EP1957537A2 (en) 2005-12-01 2008-08-20 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
WO2007085814A1 (en) * 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
TW200815470A (en) 2006-03-30 2008-04-01 Novartis Ag Compositions and methods of use for antibodies of c-Met
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
CA2658612C (en) 2006-08-03 2015-11-17 Astrazeneca Ab Antibodies directed to .alpha.v.beta.6 and uses thereof
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
AU2007293614A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
ATE536369T1 (de) * 2006-10-11 2011-12-15 Ablynx Nv Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung
JP2010511397A (ja) * 2006-12-05 2010-04-15 アブリンクス エン．ヴェー． 血清タンパク質と結合可能なペプチド
CA2672049C (en) 2006-12-08 2016-05-10 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
AU2007331672A1 (en) 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
CA2672944A1 (en) * 2006-12-22 2008-07-03 Ablynx N.V. Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders
JP2010518839A (ja) 2007-02-21 2010-06-03 アブリンクス エン．ヴェー． 血管内皮増殖因子に指向性を有するアミノ酸配列、及び過度の及び／もしくは病的な血管形成又は血管新生を特徴とする症状及び疾患を治療するためにこれを含むポリペプチド
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
CN101796072B (zh) * 2007-05-24 2014-09-24 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
AR062123A1 (es) * 2007-07-27 2008-10-15 Inst Nac De Tecnologia Agropec Dominio vhh monomerico derivado de anticuerpos de camelidos anti-vp6 dominio dimerico, metodo de inmunodeteccion de rotavirus, composiciones, metodos de prevencion y tratamiento de infecciones con rotavirus
CA2698343C (en) * 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
WO2009042589A1 (en) * 2007-09-24 2009-04-02 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses thereof
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
CA2709399C (en) * 2007-12-28 2021-01-19 Genentech, Inc. Anti-hedgehog antibodies
BRPI0907648B1 (pt) 2008-01-29 2022-01-11 Institute Of Molecular Biology And Genetics National Academy Of Science Of Ukraine Anticorpo isolado humanizado, usos de um anticorpo, métodos para preparar um anticorpo, para gerar anticorpos imunorreativos com slc34a2 e para triar ou identificar agentes ou compostos que modulam slc34a2, composições, ácido nucleico isolado, e, microorganismo hospedeiro
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
US7858729B2 (en) 2008-05-29 2010-12-28 Novomer, Inc. Methods of controlling molecular weight distribution of polymers and compositions thereof
DK2285408T3 (en) 2008-06-05 2019-02-04 Ablynx Nv AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
WO2010042815A2 (en) * 2008-10-09 2010-04-15 Duke University Vhh antibody fragments for use in the detection and treatment of cancer
US8372808B2 (en) 2008-10-31 2013-02-12 Wisconsin Alumni Research Foundation Suppression of glial fibrillary acidic protein
US10005830B2 (en) † 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
UY32514A (es) 2009-03-27 2010-10-29 Glaxo Group Ltd FUSIONES Y CONJUGADOS DE UN FÁRMACO INSULINOTRÓPICO Y dAb CON SEMIVIDA SÉRICAS MEJORADAS
EP2417163B1 (en) 2009-04-10 2019-02-27 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
US8450888B2 (en) 2009-04-20 2013-05-28 General Electric Company Integrated brushless starter/generator system
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
HUE051430T2 (hu) 2009-07-10 2021-03-01 Ablynx Nv Eljárás variábilis domének elõállítására
US8306355B2 (en) 2009-07-13 2012-11-06 Sharp Laboratories Of America, Inc. Methods and systems for reducing compression artifacts
US9644022B2 (en) * 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
US8962807B2 (en) 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
MA33930B1 (fr) 2009-12-18 2013-01-02 Sanofi Sa Nouveaux anticorps antagonistes contre gpvi et leurs fragments fab et utilisations de ceux-ci
EP3498731A1 (en) 2009-12-23 2019-06-19 ESBATech, an Alcon Biomedical Research Unit LLC Method for decreasing immunogenicity
WO2011107507A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim International Gmbh Biparatopic abeta binding polypeptides
RS66008B1 (sr) 2010-03-10 2024-10-31 Genmab As Monoklonska antitela protiv c-met
WO2011117423A1 (en) * 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
JP2013525408A (ja) 2010-04-30 2013-06-20 アブリンクス エン．ヴェー． ヘテロ二量体サイトカインｉｌ−２３のｐ１９サブユニットに指向性を有するナノボディのアミノ酸配列
SG185354A1 (en) 2010-05-20 2012-12-28 Ablynx Nv Biological materials related to her3
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
MX2013007936A (es) * 2011-01-06 2013-08-09 Glaxo Group Ltd Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta.
WO2012131053A1 (en) 2011-03-30 2012-10-04 Ablynx Nv Methods of treating immune disorders with single domain antibodies against tnf-alpha
WO2012130314A1 (en) † 2011-03-31 2012-10-04 Elara Pharmaceuticals Gmbh Composition comprising docetaxel
US20150344568A1 (en) 2011-06-23 2015-12-03 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
NZ780183A (en) 2011-06-23 2024-12-20 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2723771B1 (en) 2011-06-23 2019-09-11 Ablynx NV Serum albumin binding proteins
MX2014001019A (es) 2011-07-27 2014-05-13 Glaxo Group Ltd Dominios variables singulares anti-vgf fusionados con dominios de fc.
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
US8614548B2 (en) 2012-01-19 2013-12-24 Sonoco Development Incorporated Electroluminescent display and method for production
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
CN105643698A (zh) 2012-05-22 2016-06-08 欧文斯科宁知识产权资产有限公司 层压泡沫产品和制造层压泡沫产品的方法
WO2014111550A1 (en) † 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
PT3248986T (pt) 2014-05-16 2022-04-05 Ablynx Nv Domínios variáveis de imunoglobulina
EP3143403B1 (en) 2014-05-16 2021-10-27 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
US10118967B2 (en) 2014-10-21 2018-11-06 Ablynx N.V. Methods for treating rheumatoid arthritis by administering IL-6 receptor antibodies
NO2768984T3 (enExample) 2015-11-12 2018-06-09
EP3974449A1 (en) 2015-11-13 2022-03-30 Ablynx NV Improved serum albumin-binding immunoglobulin variable domains
HK1254952A1 (zh) 2015-11-18 2019-08-02 Merck Sharp & Dohme Llc Ctla4结合剂
CN120535622A (zh) 2015-11-18 2025-08-26 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
SG10201911035QA (en) 2015-11-18 2020-01-30 Merck Sharp & Dohme Pd1 and/or lag3 binders
CN109071639B (zh) 2015-11-18 2022-07-08 默沙东公司 Pd1/ctla4结合剂
US10626186B2 (en) 2016-01-26 2020-04-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-VWF D'D3 single-domain antibodies and methods of use
CN117164710A (zh) * 2016-12-07 2023-12-05 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白单可变结构域
ES2991459T3 (es) * 2017-01-17 2024-12-03 Ablynx Nv Ligantes de albúmina sérica mejorados
KR102778120B1 (ko) * 2017-06-02 2025-03-06 메르크 파텐트 게엠베하 Mmp13 결합성 면역글로불린
CN110997716B (zh) 2017-06-02 2024-03-15 埃博灵克斯股份有限公司 结合聚集蛋白聚糖的免疫球蛋白
LT3630847T (lt) * 2017-06-02 2024-12-10 Merck Patent Gmbh Adamts surišantys imunoglobulinai
IL270951B2 (en) * 2017-06-02 2025-05-01 Merck Patent Gmbh ADAMTS5, MMP13 and aggrecan-binding polypeptides
MY204220A (en) * 2018-02-06 2024-08-16 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
IL303783A (en) * 2020-12-18 2023-08-01 Sanofi Sa Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor

Also Published As

Publication number Publication date
KR20220114104A (ko) 2022-08-17
JP2018162305A (ja) 2018-10-18
US20140199295A1 (en) 2014-07-17
PH12013502669A1 (en) 2014-02-10
PT2723769T (pt) 2017-04-04
AU2021201506A1 (en) 2021-03-25
BR122018012485B1 (pt) 2022-09-20
US20220298227A9 (en) 2022-09-22
JP2021107426A (ja) 2021-07-29
IL250396B (en) 2022-06-01
US20170275361A1 (en) 2017-09-28
CN108653728B (zh) 2022-11-18
KR20190107200A (ko) 2019-09-18
IL250396A0 (en) 2017-03-30
JP6869923B2 (ja) 2021-05-12
IL293155A (en) 2022-07-01
RU2019128430A (ru) 2019-10-25
BR112013032145A2 (pt) 2017-12-05
BR112013032145A8 (pt) 2018-07-03
BR112013032145B1 (pt) 2022-09-20
AU2020230299A1 (en) 2020-10-01
NZ716279A (en) 2017-07-28
CN108663504A (zh) 2018-10-16
DK2723769T3 (en) 2017-04-03
KR20210047369A (ko) 2021-04-29
US20180009888A9 (en) 2018-01-11
HUE031828T2 (en) 2017-08-28
ES2622006T5 (es) 2022-10-13
US10858418B2 (en) 2020-12-08
PH12022550311A1 (en) 2023-01-23
PH12013502669B1 (en) 2018-08-10
EP2723769B1 (en) 2017-01-11
JP2014520134A (ja) 2014-08-21
KR20190041513A (ko) 2019-04-22
SG194982A1 (en) 2013-12-30
US12006352B2 (en) 2024-06-11
BR122017005075B1 (pt) 2022-09-20
DK2723769T4 (da) 2022-09-05
PH12022550310A1 (en) 2023-01-23
KR102025035B1 (ko) 2019-11-04
BR122017005075A2 (pt) 2019-09-03
CN108653728A (zh) 2018-10-16
CN104203975B (zh) 2018-05-11
KR20140040779A (ko) 2014-04-03
RU2700630C2 (ru) 2019-09-18
CA3142288A1 (en) 2012-12-27
MX2013014614A (es) 2014-08-01
KR102430693B1 (ko) 2022-08-08
US20180355031A1 (en) 2018-12-13
EP2723769A2 (en) 2014-04-30
WO2012175741A3 (en) 2013-02-14
AU2017204339A1 (en) 2017-07-13
US20200216532A1 (en) 2020-07-09
US11192938B2 (en) 2021-12-07
JP6258199B2 (ja) 2018-01-10
CA3141978A1 (en) 2012-12-27
US20210388062A1 (en) 2021-12-16
WO2012175741A2 (en) 2012-12-27
KR102880093B1 (ko) 2025-10-31
AU2020230299B2 (en) 2022-10-06
MX350074B (es) 2017-08-25
AU2024200309A1 (en) 2024-02-08
PH12022550312A1 (en) 2023-01-23
AU2019201606B2 (en) 2021-04-01
CN108659120A (zh) 2018-10-16
MX2018007826A (es) 2021-12-08
AU2019201606A1 (en) 2019-04-04
SG10201805064SA (en) 2018-07-30
US20210388061A1 (en) 2021-12-16
ZA201309295B (en) 2015-01-28
PH12022550309A1 (en) 2023-01-23
SG10201707604SA (en) 2017-11-29
IL293163A (en) 2022-07-01
US20230242620A1 (en) 2023-08-03
NZ780183A (en) 2024-12-20
LT2723769T (lt) 2017-04-10
IL229503B (en) 2022-06-01
ES2622006T3 (es) 2017-07-05
CN108659121A (zh) 2018-10-16
SG10201605048XA (en) 2016-07-28
PL2723769T3 (pl) 2017-07-31
NZ617995A (en) 2016-06-24
CA2837998A1 (en) 2012-12-27
US20170275360A1 (en) 2017-09-28
RU2014102007A (ru) 2015-11-27
KR102246924B1 (ko) 2021-04-30
AU2018202782B2 (en) 2020-07-16
PL2723769T5 (pl) 2022-10-17
KR20240033183A (ko) 2024-03-12
IL229503A0 (en) 2014-01-30
US11192937B2 (en) 2021-12-07
KR102240318B1 (ko) 2021-04-15
JP2022031790A (ja) 2022-02-22
US20220119497A1 (en) 2022-04-21
PH12017501178A1 (en) 2018-07-23
AU2012273929B2 (en) 2017-04-27
KR101965462B1 (ko) 2019-04-04
AU2018202782A1 (en) 2018-05-10
AU2017204339B2 (en) 2019-03-28
AU2021201506B2 (en) 2023-10-19
EP2723769B2 (en) 2022-06-15
JP6982400B2 (ja) 2021-12-17
JP2017160230A (ja) 2017-09-14
KR20180086280A (ko) 2018-07-30
PH12022550313A1 (en) 2023-01-23
JP2024050769A (ja) 2024-04-10
US20210403536A1 (en) 2021-12-30
CA2837998C (en) 2022-03-01
CN104203975A (zh) 2014-12-10
US20200325221A1 (en) 2020-10-15
CN108663504B (zh) 2021-06-22

Similar Documents

Publication Publication Date Title
IN2014CN00373A (enExample)
PH12012501758A1 (en) ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
EA201290311A1 (ru) Факторы риска и прогнозирование инфаркта миокарда
HK1223361A1 (zh) 用於预测肠易激综合征诊断的途径特异性测定
IN2013CN01129A (enExample)
MX2015006680A (es) Composiciones y metodos para diagnosticar tumores de tiroides.
IN2012DN03911A (enExample)
EA030186B9 (ru) Способ проведения количественных анализов
GB201111361D0 (en) Biochemical markers for neurodegenerative conditions
WO2013068374A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
EP3590959A3 (en) Pathology biomarker assay
BR112013030606A2 (pt) biomarcadores para terapia inibidora de hedgehog
WO2013188686A3 (en) Biomarker test for prediction or early detection of preeclampsia and/or hellp syndrome
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012164525A3 (en) Aging biomarkers
WO2015070001A3 (en) Compositions and methods for detecting and/or treating inflammation
MX2010000979A (es) Metodos y composiciones para tratar enfermedad autoinmune.
WO2012027266A3 (en) Methods for dectecting embryonic stem cells, induced pluripotent stem cells, or cells undergoing reprogramming to produce induced pluripotent stem cells
MX336940B (es) Uso de compuestos mejoradores de señal en deteccion de electroquimioluminiscencia.
WO2013167727A3 (en) Method for determining arthritis relapse risk
GB201206323D0 (en) Methods and arrays for use in the same
WO2012145607A3 (en) Specific copy number aberrations as predictors of breast cancer
GB201119585D0 (en) Assay
WO2013119279A3 (en) Assays and methods for the diagnosis of ovarian cancer
EP4350345A3 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains